Back
Dermata Therapeutics, Inc. (DRMA)
BiotechnologyDRMA · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$1.34
−2.90%Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for education and research only — not financial advice.
Key metrics
EPS
$-8.16
ROE
-103.6%
Gross margin
0.0%
Debt/Equity
Revenue growth
P/B ratio
Beta
Forward P/E
Dermata Therapeutics, Inc. — company intelligence
Earnings surprises
Q1 2026$-0.48 vs $-0.54 est+11.2%
Q4 2025$-1.52 vs $-1.57 est+3.2%
Q3 2025$-1.65 vs $-1.62 est-1.7%
Q2 2025$-1.66 vs $-2.96 est+43.9%
Insider activity · 90 days
0 buys1 sellnet -11 shares
Scott Kathleen D.Sell 11 · Jun 16, 2026
Recent SEC filings
4 — Insider transaction reportJun 16, 2026
8-K — Material event reportMay 27, 2026
10-Q — Quarterly reportMay 13, 2026
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
About Dermata Therapeutics, Inc.
Weekly undervalued picks (like DRMA)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.